The relationship of the genetic polymorphism of IL-6-174 and the response to benazepril treatment in patients with hypertensive renal damage
10.11958/20161498
- VernacularTitle:高血压肾损害患者IL-6-174基因多态性及其与贝那普利治疗反应的相关性研究
- Author:
Xin YU
;
Meiling YU
;
Dekai ZHANG
;
Yuankui CHU
;
Yiqing ZHANG
;
Jing BAI
;
Yiwen XING
;
Zhen YANG
- Keywords:
interleukin-6;
polymorphism;
genetic;
angiotensin-converting enzyme inhibitors;
hypertensive renal damage;
Benazepril
- From:
Tianjin Medical Journal
2017;45(5):497-501
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the relationship between the genetic polymorphism of interleukine-6 (IL-6)-174 and the response to benazepril treatment in patients with hypertensive renal damage. Methods Two hundred and eighty-four patients with hypertension were enrolled in this study. The hypertensive renal damage was defined by the measurement of urinary albumin excretion rate (UAER). One hundred and sixty healthy subjects were enrolled simultaneously as control group. Blood samples were obtained from all the subjects, and plasma levels of IL-6 and the genotype of gene IL-6-174 were detected. The patients with hypertensive renal damage were treated with benazepril for 16 weeks. The responses were evaluated by the changes of UAER level to benazepril in different genotypes. Results Genotype CC was the most common of the gene IL-6-174 in patients with hypertension, followed by GG and GC successively, with the G/C allele frequency of 47%and 53%(P<0.05), while in patients with hypertensive renal damage, GG was the most common genotype of the gene IL-6-174, followed by GC and CC successively, with the G/C allele frequency of 68%and 32%(P<0.05). After benazepril treatment, the UAER was decreased most in patients with genotype CC, followed by GC and GG successively ( P<0.05). Conclusion The G allele frequency of the gene IL-6-174 is related with hypertensive renal damage in patients in Ningxia, with GG as the most common genotype. The patients with CC genotype have the best response to benazepril treatment, with most decreased UAER.
